FDA starts speedy review of Keytruda for adjuvant kidney cancerMerck & Co is looking at a decision from the FDA in December on its application to market Share XFDA starts speedy review of Keytruda for adjuvant kidney cancerhttps://pharmaphorum.com/news/fda-starts-speedy-review-of-keytruda-for-adjuvant-kidney-cancer/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
BMS gets an important win for Opdivo combination in kidney cancerBristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the Share XBMS gets an important win for Opdivo combination in kidney cancerhttps://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
NICE rejects MSD/Pfizer’s combination in untreated kidney cancerNICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) Share XNICE rejects MSD/Pfizer’s combination in untreated kidney cancerhttps://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/
Immunicum shares fall despite “fantastic” kidney cancer dataShares in Swedish biotech Immunicum dipped sharply after it reported phase 2 results with its lead dendritic cell Share XImmunicum shares fall despite “fantastic” kidney cancer datahttps://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/
Merck and Pfizer’s Bavencio approved for renal cell carcinomaMerck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta Share XMerck and Pfizer’s Bavencio approved for renal cell carcinomahttps://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/
